Selank: Russia's anxiolytic peptide and what the research actually says

The pitch is something like: imagine a benzodiazepine that didn’t sedate you, didn’t fog your memory, didn’t build tolerance, and didn’t leave you with a withdrawal protocol on the back end. That’s how selank gets sold on the forums.

Here’s the part the forum threads skip. That description is closer to honest than the marketing usually gets — but it’s drawn almost entirely from Russian-language psychiatry journals, in studies designed differently from the placebo-controlled trials Western regulators consider definitive. The compound is real. The Russian clinical record is real. What it is not is a Western-RCT-validated anxiolytic, and the distance between those two things is the article.

A rare peptide with an actual psychiatric authorisation

Most peptides on the longevity menu are research chemicals dressed up in clinical language. Selank is one of the very few that’s been used in actual psychiatric practice — under the Russian Ministry of Health, since 2009, for generalised anxiety disorder.

Structurally it’s a synthetic heptapeptide — seven amino acids — built on tuftsin, an endogenous tetrapeptide your body produces by enzymatic cleavage of immunoglobulin G. Tuftsin’s natural role is immune signalling. Selank adds a Pro-Gly-Pro tripeptide to the C-terminus of tuftsin’s TKPR sequence, which extends the half-life from minutes to hours and shifts the pharmacology from straight immunomodulation toward central nervous system activity. The PGP extension is the same stabilising trick the Russian peptide chemistry tradition uses on semax.

The class of drug it tries to displace is the benzodiazepine. Benzos work fast for anxiety, build tolerance, build dependence, sedate you, and impair cognition. Anyone who’s been on one for any length of time knows the deal. The selling pitch for selank is mechanism: it modulates GABAergic and serotonergic signaling without binding the benzodiazepine receptor site, so the things benzos do badly — sedation, tolerance, dependence — are mechanistically uncoupled from the anxiolytic effect.

That’s a real, defensible mechanistic story. Whether it holds up in the way the marketing implies is a different question.

The animal pharmacology, briefly

Selank’s animal pharmacology is consistent across the published work.

A 2009 paper in Eksp Klin Farmakol by Semenova and colleagues compared selank and tuftsin effects on serotonin metabolism in PCPA-pretreated rats. PCPA (parachlorophenylalanine) depletes serotonin, so the model lets you ask whether a compound rebuilds the serotonergic signal in a depleted brain. Selank did. The serotonergic mechanism — modulating 5-HT availability and turnover rather than agonising a specific receptor — was established here and has held up in subsequent animal work.

A more recent 2022 paper in Bull Exp Biol Med by Konstantinopolsky and colleagues took selank into a naloxone-precipitated morphine withdrawal model in rats. A single intraperitoneal injection at the anxiolytic dose reduced the total morphine withdrawal index by 39.6%, with the convulsive-reactions component dropping significantly. Selank was slightly less potent than diazepam at the doses tested. The model is animal-only, but it speaks to the same broader story: anxiolytic activity through non-benzodiazepine mechanisms.

The broader pharmacology is captured in a 2017 Curr Med Chem review by Siebert and colleagues, which surveys 86 documents on tuftsin and its analogs across anti-tumor, anti-inflammatory, antimicrobial, and antiviral activities. Selank sits within that broader tuftsin-analog literature as the CNS-active member of the family.

So the animal mechanism story is coherent. Serotonergic modulation, anxiolytic activity, attenuation of withdrawal signs, a broader immunomodulatory background. Plausible. Reproducible across labs. The kind of animal pharmacology base that, in a Western drug-development context, would be the foundation for substantial Phase 2 work.

From a Russian rat to a Western patient is further than it looks

The clinical evidence on selank is unusual for a peptide of its kind.

Most peptides on the longevity menu have one or two published human studies, often without primary endpoints met, often in journals nobody reads. Selank has more than that — but the more is all in the Russian neuropsychiatric tradition, published in Russian, designed around comparative-effectiveness rather than placebo-controlled outcomes.

The two most-cited studies define the pattern. A 2008 paper in Zh Nevrol Psikhiatr by Zozulia and colleagues reported a comparative clinical study of selank (30 patients) versus medazepam (32 patients) in 62 adults with generalised anxiety disorder and neurasthenia. The anxiolytic effects were reported as similar to medazepam, with selank showing additional antiasthenic and psychostimulant effects — meaning the patients improved without the sedation typical of the benzodiazepine arm. The study also correlated treatment response with leu-enkephalin levels in blood serum, which gives the result a biomarker hook the marketing tends to lean on.

A 2014 paper in the same journal by Medvedev and colleagues extended that work with an open-label comparison of selank versus phenazepam — a stronger benzodiazepine than medazepam — in patients with anxiety disorders. The reported result was the same direction: comparable anxiolytic efficacy with better tolerability, no sedation, no cognitive impairment, no dependence signal in the published assessment.

Read what those studies are and aren’t. Comparative-effectiveness designs versus an active comparator (a benzodiazepine), not placebo-controlled. Sample sizes in the 60–70 range. Open-label or single-blind, not double-blind. Published in Russian-language psychiatry journals not routinely indexed in Western trial registries. The patient populations are adults with diagnosed anxiety disorders, not healthy adults using selank for cognitive sharpness or sleep quality.

That’s not a dismissal. Comparative-effectiveness work is real evidence — and demonstrating non-inferiority to an active benzodiazepine with a better tolerability profile is a meaningful clinical claim. It’s just not the same evidence base as a Cochrane-grade RCT review of an anxiolytic with full FDA marketing authorisation, and the marketing tends to flatten the difference.

The Western replication of this work is, as far as the published literature shows, essentially absent. No Western-language placebo-controlled trial of selank in GAD has been registered or published in the open-access PubMed-indexed literature that we could locate. The Russian tradition is the entire human evidence base.

What this evidence base can and can’t tell you

The 2026 Frontiers in Aging review by Mavrych and colleagues puts selank in the broader unapproved-peptide context: distinguishes agents with full FDA marketing authorisation (robust safety from large-scale trials) from non-approved peptides (limited clinical evidence, no long-term safety data), and flags significant knowledge gaps around optimal dosing, combination therapy effects, and validated biomarkers for monitoring efficacy. Selank sits squarely in the non-approved cluster. The Russian comparative-effectiveness signal is the highest-quality human evidence selank has, and Western clinical-trial reviewers don’t have a clean way to file it — it isn’t a positive placebo-controlled trial, it isn’t a null one either, and the comparative-effectiveness design the Russian tradition uses doesn’t slot neatly into a Cochrane-style evidence hierarchy.

The honest mechanistic case: GABAergic and serotonergic modulation through non-benzodiazepine pathways is interesting, the animal work supports it, the Russian comparative-effectiveness studies suggest it translates to humans without the typical benzodiazepine side-effect profile. That’s a real proposition.

The honest evidence ceiling: outside of the Russian comparative-effectiveness studies, there is essentially no controlled human evidence. Long-term safety in healthy users (the population the marketing targets) is uncharacterised. Drug interactions in a polypharmacy context aren’t studied. The PK in modern Western protocols isn’t published. Whether the anxiolytic signal holds up against placebo in a properly blinded modern trial is, twenty years into clinical use in Russia, still an open question — because that trial hasn’t been run.

The two different regulatory stories — Russian and American

Selank’s regulatory situation is unusual for compounds in this category.

In Russia, it’s been authorised by the Ministry of Health for clinical use since 2009 in the treatment of generalised anxiety disorder. That’s an actual approval, granted by an actual regulator, supported by the Russian clinical record summarised above. It’s the kind of regulatory standing most peptides on the longevity menu can’t claim anywhere.

In the United States, it has none of that standing. There’s no FDA application, no NDA, no BLA, no clinical-trial program in any indication. It is sold outside FDA-authorised channels as a research chemical.

It is also not on the PCAC July 23–24, 2026 agenda. The Federal Register notice names seven substances across the two days — BPC-157, KPV, TB-500, and MOTs-C on July 23, then Emideltide (DSIP), Semax, and Epitalon on July 24 — and selank isn’t among them. The compound currently sits outside the FDA bulk substances process entirely — neither in the established pharmaceutical framework like sermorelin, nor in the active PCAC evaluation pipeline like semax.

WADA is more straightforward. Selank isn’t named on the 2026 Prohibited List, but the S0 category — non-approved substances — uses similar-biological-effect language that reaches non-approved peptides with neurostimulant activity. If you’re tested in competition, that’s the category that applies, and the safe assumption is that the compound is off-limits regardless of how its name does or doesn’t appear in the literal list.

The trials that haven’t been run

A Western-style placebo-controlled double-blind RCT of selank in generalised anxiety disorder, with modern outcome measures (Hamilton Anxiety Scale, Beck Anxiety Inventory) and adequate sample size. That trial would either confirm the Russian comparative-effectiveness signal or fail to, and either result would be useful information. The trial hasn’t been run.

Independent replication of the no-dependence and no-cognitive-impairment claims in a controlled setting longer than the Russian studies ran. Two decades of clinical use in Russia is a meaningful real-world signal — it isn’t a longitudinal safety database.

A clean PK/PD study in healthy adults using the routes of administration most commonly prescribed (intranasal at varied doses). The PK underpinning the dosing regimens currently used is older Russian work; modern replication would strengthen or challenge it.

A serious look at the leu-enkephalin biomarker hook from Zozulia 2008. Either that correlation holds up in independent samples or it doesn’t, and either answer matters for who gets prescribed selank in a population large enough for biomarker stratification to be useful.

None of those trials are currently scheduled. The molecule has commercial demand sufficient to keep the compounding pharmacies stocked, but no Western pharmaceutical sponsor with an obvious financial incentive to fund Phase 3 work in a category where benzodiazepines remain generic, cheap, and clinically dominant.

Which leaves a reader where the article started — a compound with a real Russian clinical record, a coherent non-benzodiazepine mechanism story, an evidence base that doesn’t translate cleanly into Western regulatory expectations, and a marketing pitch that consistently overshoots both the evidence and the regulatory standing.

So — selank, in plain terms

Selank is the rare peptide where the question isn’t whether it does anything in people — the Russian psychiatric record covers that ground. The question is whether that record transfers. Russian comparative-effectiveness studies in patients with diagnosed anxiety disorders, treated by Russian physicians under a Russian Ministry of Health authorisation, don’t automatically become evidence for a healthy adult in Texas microdosing intranasally because they read about it on a podcast. The same compound. Different population. Different supervision. Different evidence.

Wolverine Health is being built so the supervision is the part you can actually get. Physician-supervised peptide service, real prescriptions, US-licensed compounding pharmacies, every batch third-party tested. The pharmacology is what the published literature says it is — we’re not going to claim more for it than the Russian record supports, and we’re not going to dismiss that record because it’s in the wrong language. Join the waitlist if you want to know the moment a legitimate version of selank — with the prescribing context that does the safety work — is actually available.